FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals

FDA Approves Merck’s CMV Drug

Nov. 15, 2017

The FDA approved Merck’s Prevymis (letermovir) for prevention of cytomegalovirus infection in adults receiving bone marrow transplants.

The CMV infection occurs in many patients receiving the transplants.

Prevymis earlier was designated a breakthrough therapy and an orphan drug by the FDA.

View today's stories